Institute of Cybernetic Surgery Cyberknife

The Institute of Cybernetic Surgery Cyberknife is a specialized cancer center in Wieliszew, Poland, established in 2011 to introduce CyberKnife robotic radiosurgery to the country. The institute serves both domestic and international patients with a focus on precision oncology and robotic radiosurgery. The center is considered unique in Poland, with leading Polish oncologists, radiologists, and surgeons on staff. The Institute holds ISO 9001:2008 certification, confirming compliance with strict medical protocols.

---

Accreditations & Recognition

• ISO 9001:2008 certification for strict medical protocols
• Recipient of a grant from the European Regional Development Fund within the Innovative Economy programme
• One of only three centers in Poland offering CyberKnife procedures

---

Medical Specialties

---

Facilities

• CyberKnife VSI 1000 system delivering precise radiation therapy; RapidArc technology for highly accurate radiation therapy; TrueBeam system combining radiation and radiosurgery
• State-of-the-art infrastructure including CT labs, treatment rooms, and neurosurgical consultations
• Research Center working closely with the Faculty of Physics of the University of Warsaw

---

International Patient Services

• Multilingual medical staff and streamlined treatment process for international patients
• Airport transfer service available at patient request
• Comfortable facilities accommodating patients of all categories, including those with disabilities

---

Patient Experience

The Institute is equipped with the latest CyberKnife systems, which allow doctors to perform complex procedures without traditional surgery, meaning no incisions, no need for anesthesia, and a much shorter recovery period. The success rate of CyberKnife therapy reaches 98%, with most localized tumors removed in 1–2 sessions, and unlike conventional surgery, CyberKnife requires no incisions or anesthesia, with the risk of complications 10 times lower. Treatment costs are 2–3 times cheaper than in Western Europe and 5–7 times lower than in the U.S.